More transparency needed
This article was originally published in Scrip
While it was no surprise that the regulators have come down heavy on GSK's Avandia, the news that the US Food & Drug Administration and the European Medicines Agency should diverge in their response to well documented safety concerns was less predictable. Of course there would be more regulatory certainty if the European assessment processes were more transparent.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.